Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
Vera E R AsscherVince B C BiemansMarieke J PierikGerard DijkstraMark LöwenbergSander van der MarelNanne K H de BoerAlexander G L BodelierJeroen M JansenRachel L WestJeoffrey J L HaansWillemijn A van DopRinse K WeersmaFrank HoentjenP W Jeroen Maljaarsnull nullPublished in: Alimentary pharmacology & therapeutics (2020)
Comorbidity - but not age - is associated with an increased risk of hospitalisations on either treatment, and with any infection on vedolizumab. This underlines the importance of comorbidity assessment and safety monitoring of IBD patients.
Keyphrases
- patients with inflammatory bowel disease
- end stage renal disease
- ulcerative colitis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- study protocol
- case report
- type diabetes
- adipose tissue
- metabolic syndrome
- patient reported outcomes
- cross sectional
- skeletal muscle
- combination therapy
- double blind
- patient reported
- weight loss
- glycemic control